Published in Biotech Business Week, August 8th, 2005
The program was developed around ImaRx's existing suite of oxygen delivery patents and advanced nanobubble emulsion technologies in addition to four U.S. patents that the company has exclusively sublicensed from Sonus Pharmaceuticals, Inc. The patents cover compositions of matter and methods of using oxygen delivery for treatment of disease.
"ImaRx has strengthened our existing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.